In both rodents and humans, peripheral administration of amylin reduces food intake, delays gastric emptying, and suppresses postprandial glucagon secretion, underscoring its potential in managing metabolic disorders such as type 2 diabetes [18,19]. This evidence concerns the gene IAPP and metabolic disease.